Greg Brown, M.D.
Advisory Board - Healthcare Royalty Investing Pioneer
Gregory B. Brown, M.D. is CEO and a Director of Memgen, Inc, a development-stage company which is a leader in the development of next-generation viral immunotherapeutics including oncolytic viruses. Dr. Brown was a co-founder of HCR Partners, a healthcare-focused asset management firm, and serves on that firm’s Senior Advisor Board. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led an HMO. He brings broad expertise in the scientific, technical, clinical and medical evaluation of product candidates as well as in the strategic clinical development of biopharmaceutical products. He has been involved in sourcing, diligencing and closing more than $1 billion of private healthcare principal investments.
Before co-founding HCR, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. Through his career, Dr. Brown has served on the boards of more than twenty healthcare companies, including both public and private companies. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International.
Dr. Brown holds a B.A. from Yale College, an M.D. from SUNY Upstate Medical Center and an M.B.A. from Harvard Business School. He currently serves as an independent director on the boards of Aquestive Therapeutics, Inc.; Caladrius Biosciences, Inc.; Faron Pharmaceuticals Oy; and FAST BioMedical.